India, March 10 -- Shares of Biodexa Pharmaceuticals Plc (BDRX) jumped over 32% on Monday morning after the clinical stage biopharmaceutical company announced successful outcome of a Type C meeting with the U.S. Food And Drug Administration regarding the phase 3 program for eRapa in familial adenomatous polyposis.
BDRX is currently trading at $4.0300, up $0.9800 or 32.1312%, on a heavy volume of 20 million shares, above average volume of 0.5 million, on the Nasdaq. The stock opened its trading at $4.2000 after closing Friday at $3.0500. The stock has traded between $2.7800 and $74.0000 in the past 52-week period.
Biodexa Pharmaceuticals announced the results of its Type C meeting with the FDA regarding the protocol for the planned registr...